Nasdaq Grants Revelation Biosciences Inc. Continued Listing
Revelation Biosciences (NASDAQ: REVB) has secured continued listing on the Nasdaq Stock Market following a decision by the Nasdaq Hearings Panel. The company must maintain its stock price at or above $1.00 for at least ten consecutive trading days by February 14, 2025. The Panel also confirmed REVB's compliance with the Equity Requirement of Listing Rule 5550(b)(1), addressing a previous delisting notice from August 14, 2024.
Recent developments include a successful $4 million warrant exercise on December 3, 2024, and FDA acceptance of the Gemini IND on December 2, 2024. The company plans to initiate a Phase 1b clinical study for chronic kidney patients in the first half of 2025, following the successful GMP manufacture of the Gemini drug product for clinical trials.
Revelation Biosciences (NASDAQ: REVB) ha ottenuto la conferma della sua quotazione continua sul mercato azionario Nasdaq a seguito di una decisione del Nasdaq Hearings Panel. La societ脿 deve mantenere il prezzo delle sue azioni a $1,00 o superiore per almeno dieci giorni di trading consecutivi entro il 14 febbraio 2025. Il Panel ha anche confermato la conformit脿 di REVB con il Requisito di Equity della Regola di Quotazione 5550(b)(1), affrontando un precedente avviso di delisting del 14 agosto 2024.
Sviluppi recenti includono un esercizio di warrant di successo da $4 milioni il 3 dicembre 2024 e l'accettazione da parte della FDA del Gemini IND il 2 dicembre 2024. L'azienda prevede di avviare uno studio clinico di Fase 1b per pazienti con malattie renali croniche nella prima met脿 del 2025, a seguito della fabbricazione GMP di successo del prodotto farmaceutico Gemini per sperimentazioni cliniche.
Revelation Biosciences (NASDAQ: REVB) ha asegurado su continuidad en el mercado de valores Nasdaq tras una decisi贸n del Nasdaq Hearings Panel. La compa帽铆a debe mantener el precio de sus acciones en $1.00 o m谩s durante al menos diez d铆as de negociaci贸n consecutivos antes del 14 de febrero de 2025. El Panel tambi茅n confirm贸 el cumplimiento de REVB con el Requisito de Capital de la Regla de Cotizaci贸n 5550(b)(1), en respuesta a un aviso de exclusi贸n anterior del 14 de agosto de 2024.
Los desarrollos recientes incluyen un ejercicio exitoso de warrants por $4 millones el 3 de diciembre de 2024 y la aceptaci贸n por parte de la FDA de Gemini IND el 2 de diciembre de 2024. La compa帽铆a planea iniciar un estudio cl铆nico de Fase 1b para pacientes con enfermedad renal cr贸nica en la primera mitad de 2025, despu茅s de la exitosa fabricaci贸n bajo GMP del producto farmac茅utico Gemini para ensayos cl铆nicos.
Revelation Biosciences (NASDAQ: REVB)電� Nasdaq 觳 鞙勳洂須岇潣 瓴办爼鞐� 霐半澕 Nasdaq 歃濌秾 瓯半灅靻岇棎靹滌潣 靸侅灔 歆�靻嶌潉 頇曤炒頄堨姷雼堧嫟. 須岇偓電� 2025雲� 2鞗� 14鞚缄箤歆� 鞝侅柎霃� 10鞚� 鞐办啀鞙茧 欤缄皜毳� $1.00 鞚挫儊 鞙犾頃挫暭 頃╇媹雼�. 鞙勳洂須岆姅 霕愴暅 REVB臧� 2024雲� 8鞗� 14鞚检潣 鞚挫爠 靸侅灔 韽愳 韱奠鞕� 甏�霠晿鞐� 靸侅灔 攴滌箼 5550(b)(1)鞚� 歆�攵� 鞖旉惮靷暛鞚� 欷�靾橅晿瓿� 鞛堨潓鞚� 頇曥澑頄堨姷雼堧嫟.
斓滉芳 歆勴枆霅� 靷暛鞙茧電� 2024雲� 12鞗� 3鞚检棎 歆勴枆霅� 靹标车鞝侅澑 $4 氚彪鞚� 鞗岆煱韸� 頄夓偓鞕� 2024雲� 12鞗� 2鞚� FDA鞚� Gemini IND 鞀轨澑 霌膘澊 鞛堨姷雼堧嫟. 須岇偓電� 鞛勳儊 鞁滍棙鞚� 鞙勴暅 Gemini 鞎诫 鞝滍拡鞚� 靹标车鞝侅澑 GMP 鞝滌“ 鞚错泟 2025雲� 靸侂皹旮办棎 毵岇劚 鞁犾灔 頇橃瀽毳� 鞙勴暅 1b 雼硠鞚� 鞛勳儊 鞐瓣惮毳� 鞁滌瀾頃� 瓿勴殟鞛呺媹雼�.
Revelation Biosciences (NASDAQ: REVB) a s茅curis茅 sa cotation continue sur le march茅 boursier Nasdaq suite 脿 une d茅cision du Nasdaq Hearings Panel. La soci茅t茅 doit maintenir le prix de ses actions 脿 1,00 $ ou plus pendant au moins dix jours de trading cons茅cutifs avant le 14 f茅vrier 2025. Le Panel a 茅galement confirm茅 que REVB respectait l'exigence de capital de la r猫gle de cotation 5550(b)(1), en r茅ponse 脿 un avis de radiation pr茅c茅dent du 14 ao没t 2024.
Les d茅veloppements r茅cents incluent un exercice de bons de souscription r茅ussi de 4 millions de dollars le 3 d茅cembre 2024 et l'acceptation par la FDA du Gemini IND le 2 d茅cembre 2024. La soci茅t茅 pr茅voit de lancer une 茅tude clinique de Phase 1b pour des patients atteints de maladies r茅nales chroniques au cours de la premi猫re moiti茅 de 2025, apr猫s la fabrication GMP r茅ussie du produit pharmaceutique Gemini pour les essais cliniques.
Revelation Biosciences (NASDAQ: REVB) hat die Fortsetzung der Notierung am Nasdaq Aktienmarkt nach einer Entscheidung des Nasdaq Hearings Panels gesichert. Das Unternehmen muss den Aktienkurs bis zum 14. Februar 2025 mindestens zehn aufeinanderfolgende Handelstage lang bei oder 眉ber $1,00 halten. Das Panel best盲tigte auch die Einhaltung der Eigenkapitalanforderungen gem盲脽 der Listing-Regel 5550(b)(1) in Bezug auf eine vorherige Delisting-Mitteilung vom 14. August 2024.
Zu den j眉ngsten Entwicklungen geh枚rt ein erfolgreicher Warrantaus眉bung von $4 Millionen am 3. Dezember 2024 sowie die Akzeptanz des Gemini IND durch die FDA am 2. Dezember 2024. Das Unternehmen plant, in der ersten H盲lfte von 2025 eine Phase 1b-Studie f眉r Patienten mit chronischen Nierenerkrankungen zu starten, nachdem die GMP-Herstellung des Gemini-Arzneimittels f眉r klinische Studien erfolgreich abgeschlossen wurde.
- Successfully raised $4 million through warrant exercise
- FDA acceptance of Gemini IND
- Regained compliance with Nasdaq listing requirements
- Completed GMP manufacture of Gemini drug product
- Must maintain $1.00 stock price requirement by February 2025 to avoid delisting
- Previous delisting notice in August 2024 indicates financial stability concerns
Insights
The Nasdaq panel's decision to maintain REVB's listing represents a critical regulatory reprieve, particularly following the company's successful <money>$4 million</money> warrant exercise in December. The company must now achieve and maintain a <money>$1.00</money> share price by February 14, 2025 - a significant challenge given current market conditions and the company's micro-cap status. The equity requirement compliance confirmation eliminates one major regulatory hurdle, but the share price requirement remains crucial.
The recent <money>$4 million</money> capital injection strengthens the balance sheet and provides runway for the upcoming Phase 1b trial. However, investors should note that clinical-stage biotech companies typically require substantial ongoing capital and future dilutive financing remains a possibility.
The FDA's acceptance of the Gemini IND marks a pivotal regulatory milestone, enabling progression into clinical trials for chronic kidney disease patients. The successful GMP manufacturing achievement demonstrates operational execution in drug development fundamentals. The planned Phase 1b study initiation in H1 2025 provides a clear near-term catalyst, though early-stage clinical trials carry inherent risks.
The company's trained immunity platform represents an innovative approach to treating disease, but investors should understand that this is still an early-stage, high-risk therapeutic strategy. The transition from SPAC-related obligations to focused clinical development could improve operational efficiency, though significant clinical validation work remains ahead.
Additionally, the Nasdaq Hearings Panel confirmed that the Company has regained compliance with the Equity Requirement of Listing Rule 5550(b)(1) for which the Company was issued a notice of delisting for failure to comply with Equity Requirement of Listing Rule 5550(b)(1) on August 14, 2024.
鈥淲e are very thankful to the Nasdaq Hearings Panel for recognizing the significant progress made following the tumultuous time for the Company post SPAC merger,鈥� said James Rolke, Chief Executive Officer of Revelation. 鈥淣ow that our obligations from the SPAC merger have settled, we can focus on the development of Gemini and we look forward to the initiation of our Phase 1b clinical study in chronic kidney patients shortly.鈥�
On December 3, 2024, the Company announced the successful exercise of warrants for
For more information on Revelation, please visit .
About Gemini
Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD庐) that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner. Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Earlier this year Revelation announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity as observed through expected changes in multiple biomarkers including upregulation of IL-10.
Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program). In addition, Gemini may be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program).
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit .
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management鈥檚 expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation鈥檚 product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation鈥檚 balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
View source version on businesswire.com:
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
Source: Revelation Biosciences, Inc.
FAQ
What is the deadline for REVB to meet Nasdaq's $1.00 stock price requirement?
How much did REVB raise through warrant exercise in December 2024?
When will REVB begin its Phase 1b clinical study for Gemini?
What recent regulatory milestone did REVB achieve for Gemini?
